ArticleDiabetes, obesity & metabolism2026

A Phase 2 Trial of Frexalimab, a CD40L Antagonist, in Adolescents and Adults With Recent-Onset Type 1 Diabetes (FABULINUS): Rationale and Study Design.

Andriy Cherkas et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.